These guidelines, developed by the Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS) are a set of rules developed to assist medical coders in assigning the appropriate codes. The guidelines are based on the coding and sequencing instructions from the Tabular List and the Alphabetic Index in ICD-10-CM. Show These guidelines are for medical coders who are assigning diagnosis codes in a hospital, outpatient setting, doctor’s office or some other patient setting. The guidelines for coding Neoplasms are below. These can be found in the “ICD-10-CM Official Guidelines for Coding and Reporting FY 2019” and can be found on pages 29-36. For a complete listing of the guidelines, see http://www.cdc.gov/nchs/icd/icd10cm.htm. Chapter 2: Neoplasms (C00-D49): General guidelinesChapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms, such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary (metastatic) sites should also be determined. Primary malignant neoplasms overlapping site boundariesA primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned. Malignant neoplasm of ectopic tissueMalignant neoplasms of ectopic tissue are to be coded to the site of origin mentioned, e.g., ectopic pancreatic malignant neoplasms involving the stomach are coded to malignant neoplasm of pancreas, unspecified (C25.9). The neoplasm table in the Alphabetic Index should be referenced first. However, if the histological term is documented, that term should be referenced first, rather than going immediately to the Neoplasm Table, in order to determine which column in the Neoplasm Table is appropriate. Alphabetic Index to review the entries under this term and the instructional note to “see also neoplasm, by site, benign.” The table provides the proper code based on the type of neoplasm and the site. It is important to select the proper column in the table that corresponds to the type of neoplasm. The Tabular List should then be referenced to verify that the correct code has been selected from the table and that a more specific site code does not exist. See Section I.C.21. Factors influencing health status and contact with health services, Status, for information regarding Z15.0, codes for genetic susceptibility to cancer. a. Treatment directed at the malignancy If the treatment is directed at the malignancy, designate the malignancy as the principal diagnosis. The only exception to this guideline is if a patient admission/encounter is solely for the administration of chemotherapy, immunotherapy or external beam radiation therapy, assign the appropriate Z51. -- code as the first-listed or principal diagnosis, and the diagnosis or problem for which the service is being performed as a secondary diagnosis. b. Treatment of secondary site When a patient is admitted because of a primary neoplasm with metastasis and treatment is directed toward the secondary site only, the secondary neoplasm is designated as the principal diagnosis even though the primary malignancy is still present. c. Coding and sequencing of complications Coding and sequencing of complications associated with the malignancies or with the therapy thereof are subject to the following guidelines:
d. Primary malignancy previously excised When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code. e. Admissions/Encounters involving chemotherapy, immunotherapy and radiation therapy
f. Admission/encounter to determine extent of malignancy When the reason for admission/encounter is to determine the extent of the malignancy, or for a procedure such as paracentesis or thoracentesis, the primary malignancy or appropriate metastatic site is designated as the principal or first-listed diagnosis, even though chemotherapy or radiotherapy is administered. g. Symptoms, signs, and abnormal findings listed in Chapter 18 associated with neoplasms Symptoms, signs, and ill-defined conditions listed in Chapter 18 characteristic of, or associated with, an existing primary or secondary site malignancy cannot be used to replace the malignancy as principal or first-listed diagnosis, regardless of the number of admissions or encounters for treatment and care of the neoplasm. See section I.C.21. Factors influencing health status and contact with health services, Encounter for prophylactic organ removal. h. Admission/encounter for pain control/management See Section I.C.6. for information on coding admission/encounter for pain control/management. i. Malignancy in two or more noncontiguous sites A patient may have more than one malignant tumor in the same organ. These tumors may represent different primaries or metastatic disease, depending on the site. Should the documentation be unclear, the provider should be queried as to the status of each tumor so that the correct codes can be assigned. j. Disseminated malignant neoplasm, unspecified Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites. k. Malignant neoplasm without specification of site Code C80.1, Malignant (primary) neoplasm, unspecified, equates to Cancer, unspecified. This code should only be used when no determination can be made as to the primary site of a malignancy. This code should rarely be used in the inpatient setting. l. Sequencing of neoplasm codes
m. Current malignancy versus personal history of malignancy When a primary malignancy has been excised but further treatment, such as an additional surgery for the malignancy, radiation therapy or chemotherapy is directed to that site, the primary malignancy code should be used until treatment is completed. When a primary malignancy has been previously excised or eradicated from its site, there is no further treatment (of the malignancy) directed to that site, and there is no evidence of any existing primary malignancy, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Subcategories Z85.0-Z85.7 should only be assigned for the former site of the malignancy, not the site of a secondary malignancy. Codes from subcategory Z85.8-maybe be assigned for the former site(s) of either a primary or secondary malignancy included in this subcategory. See Section I.C.21. Factors influencing health status and contact with health services, History (of) n. Leukemia, Multiple Myeloma, and Malignant Plasma Cell Neoplasms in remission versus personal history The categories for leukemia, and category C90, Multiple myeloma and malignant plasma cell neoplasms, have codes indicating whether or not the leukemia has achieved remission. There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried. See Section I.C.21. Factors influencing health status and contact with health services, History (of) o. Aftercare following surgery for neoplasm See Section I.C.21. Factors influencing health status and contact with health services, Aftercare p. Follow-up care
for completed treatment of a malignancy See Section I.C.21. Factors influencing health status and contact with health services, Follow-up q. Prophylactic organ removal for prevention of malignancy See Section I.C. 21, Factors influencing health status and contact with health services, Prophylactic organ removal r. Malignant neoplasm associated with transplanted organ A malignant neoplasm of a transplanted organ should be coded as a transplant complication. Assign first the appropriate code from category T86.-, Complications of transplanted organs and tissue, followed by code C80.2, Malignant neoplasm associated with transplanted organ. Use an additional code for the specific malignancy. Updated: December 3, 2018 What is the ICDICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
What ICDICD-10 code R11 for Nausea and vomiting is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .
What is the ICD1 for Encounter for antineoplastic chemotherapy and immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
What is the ICDICD-10 code: Z92. 6 Personal history of chemotherapy for neoplastic disease.
|